Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

Affordable Access

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

Authors
Publisher
Nature Publishing Group
Keywords
  • Male
  • Female
  • Prognosis
  • Humans
  • Adult
  • Antibodies
  • Middle Aged
  • Neoplasm Staging
  • Tumor Markers
  • Treatment Outcome
  • Prospective Studies
  • Aged
  • Survival Rate
  • Antineoplastic Combined Chemotherapy Protocols/*Therapeutic Use
  • Neoplasm Recurrence
  • Fluorouracil/Administration & Dosage
  • Leucovorin/Administration & Dosage
  • Biological/*Analysis
  • Monoclonal/Administration & Dosage
  • Liver Neoplasms/Chemistry/*Drug Therapy/Secondary
  • Local/Diagnosis/Drug Therapy
  • Organoplatinum Compounds/Administration & Dosage
  • Peritoneal Neoplasms/Chemistry/*Drug Therapy/Secondary
  • Stomach Neoplasms/Chemistry/*Drug Therapy/Pathology

Abstract

This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers. Patients received cetuximab 400 mg m(-2) at week 1 and 250 mg m(-2) weekly thereafter until disease progression. Oxaliplatin (100 mg m(-2)) and leucovorin (100 mg m(-2)) were administered as a 2-h infusion followed by a 46-h continuous infusion of 5-fluorouracil (2400 mg m(-2)) every 2 weeks for a maximum of 12 cycles. Biomarkers potentially associated with efficacy were analysed. Among 38 evaluable patients, confirmed response rate (RR) was 50.0% (95% CI 34.1-65.9). Median time-to-progression (TTP) was 5.5 months (95% CI 4.5-6.5) and overall survival (OS) 9.9 months. Eleven patients having tumour EGFR expression by immunohistochemistry with low serum EGF and TGF-alpha levels showed a 100% RR compared to 37.0% in the remaining 27 patients (P<0.001). Moreover, ligand level increased when disease progressed in seven out of eight patients with EGFR expression and low baseline ligand level. No patient exhibited EGFR amplification or K-ras mutations. Gastric cancer patients with EGFR expression and low ligand levels had better outcomes with cetuximab/mFOLFOX6 treatment.

There are no comments yet on this publication. Be the first to share your thoughts.